113 results about "Interleukin-1beta" patented technology

A method for treating patients with renal failure includes administering to them an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor necrosis factor alpha, interferon gamma, interleukin 6 and interleukin 1 beta. Soluble cytokine receptors also can be employed. The method can be used as a supplement to or as partial or complete replacement for dialysis. A pharmaceutical composition includes antibody or functional equivalent thereof to urea, creatinine, or both; antibody, functional equivalent or soluble cytokine receptor to tumor necrosis factor alpha, interferon gamma, interleukin 6, interleukin 1 beta or any combination thereof The composition can be included in a kit.

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator / filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in the affected joint of a mammal is accomplished by administering a chondroprotective compound of Formula (I):where A is hydroxy, (C1-C4)alkoxy, amino, hydroxy-amino, mono-(C1-C2)alkylamino, di-(C1-C2)alkylamino; X and Y are independently H or (C1-C2)alkyl; and n is 1 or 2; R6 is halogen, (C1-C3)alkyl, trifluoromethyl, or nitro; R9 is H; (C1-C2)alkyl; phenyl or phenyl-(C1-C2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; -C(=O)-R, where R is (C1-C2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or -C(=O)-O-R', where R1 is (C1-C2)alkyl.This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration. Whether or not a mammal needs such treatment is determined by whether or not it exhibits a statistically significant deviation from normal standard values in synovial fluid or membrane from the affected joint, with respect to at least five of the following substances: increased interleukin-1 beta (IL-1beta); increased tumor necrosis factor alpha (TNFalpha); increased ratio of IL-1beta to IL-1 receptor antagonist protein (IRAP); increased expression of p55 TNF receptors (p55 TNF-R); increased interleukin-6 (IL-6); increased leukemia inhibitory factor (LIF); decreased insulin-like growth factor-1 (IGF-1); decreased transforming growth factor beta (TGFbeta); decreased platelet-derived growth factor (PDGF); decreased basic fibroblast growth factor (b-FGF); increased keratan sulfate; increased stromelysin; increased ratio of stromelysin to tissue inhibitor of metalloproteases (TIMP); increased osteocalcin; increased alkaline phosphatase; increased cAMP responsive to hormone challenge; increased urokinase plasminogen activator (uPA); increased cartilage oligomeric matrix protein; and increased collagenase.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator / filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1B) receptor antagonist (IL-1Ra), such as anakinra.

The invention relates to a grass carp interleukin 1 beta gene and protein and a recombinant expression method thereof. The invention provides the grass carp interleukin 1 beta gene and the grass carp interleukin 1 beta protein coded by the gene. The recombinant expression method of the invention adopts homology cloning technology to clone and obtain the cDNA complete sequence of the grass carp interleukin 1 beta gene, uses the mature peptide sequence of the grass carp interleukin 1 beta gene to construct a prokaryotic expression vector and screens out a recombinant expression system used for efficiently expressing the grass carp interleukin 1 beta gene. The recombinant expression method of the invention comprises the following steps: 1. performing gene cloning; 2. constructing and screening the recombinant expression vector; and 3. expressing the recombinant protein, and separating and purifying the expression products. The beneficial effect of the invention is that the technical scheme of the invention can be used to perform the industrialized production of the recombinant interleukin 1 beta, and the recombinant interleukin 1 beta can be used in the theoretical research of the immunologic mechanism of fish.

The invention provides methods and reagents for detecting a polymorphism associated with in an upstream region of the interleukin-1 beta (IL-B) gene (IL-1B (−3737)) that affects transcription of the gene and susceptibility to inflammatory and infectious diseases such as periodontal disease and Alzheimer's disease.

The invention discloses a compound probiotic preparation. The compound probiotic preparation is characterized by being composed of bacillus licheniformis, saccharomyces cerevisiae, bifidobacterium animalis, lactobacillus acidophilus, streptococcus thermophilus, tryptophan, xylo-oligosaccharides, galactomannan and zinc lactate. The compound probiotic preparation disclosed by the invention is capable of effectively improving growth conditions of piglets so as to increase daily weight gain and reduce diarrhea rate; moreover, the compound probiotic preparation is also capable of increasing levelsof interleukin-1-beta (IL-1-beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and intestinal mucosa SIgA in the piglet body so as to enhance disease resistance of the piglets, as well as helping the piglets to establish healthy intestinal flora environment. In addition, the compound probiotic preparation is low in production cost as well as easy to promote and use, and has wideapplication prospects.

The invention discloses a breeding method of a new disease-resistance large white pig strain. The method includes the following steps that 1, a feed adding method is adopted to conduct an Escherichia coli infection experiment on weaned piglets of a core group in large white pigs, and an Escherichia coli resistant breeding basic group in the large white pigs is established; 2, concentration determination is conducted on cytokines of interleukin 1beta, interleukin 4, interleukin 6, interleukin 8, interleukin 10, transforming growth factor beta, tumor necrosis factor alpha and interferon gamma of an Escherichia coli resistant population in the basic group; reproductive performances are detected and selected, growth speeds, lean meat ratios and carcass quality characters, and a first generation is established; 3, a group subculture selective breeding method and a molecular-marker-assisted selection method are adopted. In this way, by the adoption of the breeding method of the new disease-resistance large white pig strain, after four to five generations, a vested breeding target is achieved gradually, a new-strain core group is established, and the morbidity of piglet diarrheal diseases is expected to be reduced.